- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06887764
Robotic Knee Orthosis-assisted Walking in CP
June 16, 2026 updated by: David Scher, MD, Hospital for Special Surgery, New York
A Pilot Study to Examine the Effect of a Powered Knee Orthosis on Crouch Gait in Cerebral Palsy
Robotic exoskeletons are becoming increasingly accepted to provide upright mobility in individuals with neurological disorders.
These devices can assist in overcoming gravitational forces and reduce energy consumption.
Agilik is one such device intended for individuals with neurological disorders.
However, Agilik is relatively new, and its efficacy in individuals with CP is unknown.
Therefore, this study aims to assess the effectiveness of Agilik as an assistive device for individuals with CP and crouch gait.
In this pilot study, ten individuals with CP, GMFCS levels I and II, and crouch gait will walk with Agilik under the supervision of a physical therapist.
Assessments of walking with shoes or AFO and Agilik will evaluate the efficacy of the device.
The pilot study will assess if Agilik decreases crouch and improves gait characteristics in individuals with CP.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Robotic knee orthosis (RKO) can assist with voluntary knee extension and potentially reduce crouch/flexed-knee gait, but the effectiveness of this technology in individuals with CP is unknown.
This study aims to assess the efficacy of Agilik as an assistive device for individuals with CP.
Ten individuals with CP, ages 8 to 65 years, and at GMFCS levels I and II, will be recruited for this pilot study.
Each individual will participate in a maximum of four sessions/ visits.
The first three sessions will include RKO device fitting and tuning, followed by RKO-assisted walking practice to help with device acclimation.
These sessions will last up to 60 minutes.
A two-minute walk test (2MWT) will also be conducted at the first visit, which will serve as a reference to assess any shift in endurance from device-tuning/ practice.
The final visit will include 2MWT and 3D motion capture in shod (shoes or shoes+AFO) and RKO-assisted (shoes+RKO or shoes+AFO+RKO) conditions, and may take up to 3 to 4 hours.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Hospital for Special Surgery
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed with cerebral palsy at GMFCS levels I and II
- Exhibits crouch gait
- Between 8 to 65 years of age
- Hip flexion contracture less than 10 degrees
- Knee flexion contracture less than 20 degrees when measured in prone with hips extended
- Thigh-foot angle is between 15 degrees (internal) to 30 degrees (external) in prone
- Can walk a minimum distance of 10 meters without stopping
Exclusion Criteria:
- No other neurological, musculoskeletal, or cardiorespiratory health conditions or injuries
- The presence of any cognitive impairment that could limit the ability to understand, follow simple directions, and inform when in pain
- Inability to participate in the study because of recent orthopedic surgery (within twelve months)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Effect of a powered knee orthosis in individuals with Cerebral Palsy and Flexed-knee Gait
|
The investigators will assess walking in each of the following conditions: shod (shoes or shoes+AFO) and RKO-assisted (shoes+RKO or shoes+AFO+RKO), to achieve the following: (1) Evaluate the effect of RKO, compared to shod upon endurance in individuals with CP at GMFCS levels I and II, and (2) Evaluate the effect of RKO, compared to shod, upon temporal-spatial parameters, lower limb sagittal joint kinematics, and muscle EMG in individuals with CP at GMFCS levels I and II.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Distance from 2MWT
Time Frame: From enrollment until data collection is performed on the fourth study session.
|
The distance covered by participants during a two-minute walking test (2MWT) will be compared between RKO-assisted and shod conditions.
|
From enrollment until data collection is performed on the fourth study session.
|
|
Step length
Time Frame: At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
Mean step length (distance between the two feet measured from the heel of one foot to the heel of the contralateral foot while both feet are on the ground) during walking will be compared between RKO-assisted and shod conditions.
|
At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
|
Single limb support time
Time Frame: At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
Mean single limb support time (duration just one foot by itself is on the ground) during walking will be compared between RKO-assisted and shod conditions.
|
At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
|
Walking speed
Time Frame: At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
Mean walking speed during walking will be compared between RKO-assisted and shod conditions.
|
At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
|
Lower limb joint kinematics
Time Frame: At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
The sagittal plane lower limb joint angles (degrees) during walking will be compared to evaluate the difference between RKO-assisted and shod conditions.
|
At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
|
Binary indicator of improvement in walking distance with RKO use
Time Frame: At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
"Yes" if the walking distance in the RKO-assisted condition was greater than shod, and "No" if there was no improvement.
|
At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
|
Lower limb electromyography data
Time Frame: At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
Electromyography (EMG) amplitude and duration of lower limb anti-gravity muscles (rectus femoris, vastus lateralis, vastus medialis, medial gastrocnemius, soleus, and gluteus maximus) will be compared between RKO-assisted and shod conditions.
The EMG data will be filtered and rectified to compute linear envelopes.
From these envelopes, the average value of EMG amplitude and duration will be compared between RKO-assisted and shod conditions.
|
At the end of the study visit for each participant, data collection will be performed during the fourth study session from enrollment.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 10, 2025
Primary Completion (Actual)
April 25, 2026
Study Completion (Actual)
April 25, 2026
Study Registration Dates
First Submitted
March 7, 2025
First Submitted That Met QC Criteria
March 14, 2025
First Posted (Actual)
March 20, 2025
Study Record Updates
Last Update Posted (Actual)
June 18, 2026
Last Update Submitted That Met QC Criteria
June 16, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-2299
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The study results (de-identified) will be disseminated in conference abstracts and peer-reviewed journal articles.
IPD Sharing Time Frame
Within 12 months of the trial completion.
IPD Sharing Access Criteria
Data and supporting information will be shared upon reasonable request to the PI.
After the PI reviews and approves the applicant's request, de-identified information will be provided.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Palsy (CP)
-
Ibadat International University, IslamabadRecruitingCerebral Palsy (CP) | Athetoid CPPakistan
-
IRCCS Fondazione Stella MarisUniversity of Siena, ItalyRecruitingCerebral Palsy (CP) | Motor Imagery | CP (Cerebral Palsy) | Action ObservationItaly
-
Cairo UniversityCompletedCerebral Palsy (CP) | Unilateral Cerebral PalsyEgypt
-
University of California, San FranciscoNot yet recruitingCerebral Palsy | Cerebral Palsy (CP) | Infant | Cerebral Palsy InfantileUnited States
-
Holland Bloorview Kids Rehabilitation HospitalCanadian Institutes of Health Research (CIHR)RecruitingCerebral Palsy (CP) | Hemiplegic Cerebral PalsyCanada
-
International Clinic of Rehabilitation, UkraineElita Rehabilitation CenterRecruitingCerebral Palsy (CP)Ukraine
-
University of ThessalyNot yet recruiting
-
Centre Médico-Chirurgical de Réadaptation des Massues...Recruiting
-
Baylor UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingCerebral Palsy (CP)United States
-
Istanbul University - CerrahpasaActive, not recruitingCerebral Palsy (CP)Turkey (Türkiye)
Clinical Trials on RKO-assisted walking in individuals with CP
-
University of ManitobaCompleted
-
University of SydneyCompleted
-
Vanda PharmaceuticalsRecruitingSleep Disturbances in Smith-Magenis SyndromeUnited States
-
The Hong Kong Polytechnic UniversityHarvard Medical School (HMS and HSDM); Chinese University of Hong KongUnknown
-
Hasan Kalyoncu UniversityWithdrawnCarpal Tunnel Syndrome
-
University of Modena and Reggio EmiliaArcispedale Santa Maria Nuova-IRCCSCompletedCerebral Palsy | Diplegia, SpasticItaly
-
IRCCS Fondazione Stella MarisCompleted
-
Changhai HospitalCompletedChronic Pancreatitis | Pancreatic Exocrine InsufficiencyChina
-
Brunel UniversityRoyal National Orthopaedic Hospital NHS TrustActive, not recruitingSpinal Cord InjuryUnited Kingdom
-
Instituto do Cancer do Estado de São PauloRecruiting